InCred Asset Management is cautious about US-facing generic pharma companies due to potential tariff risks and single-digit earnings growth. They favor domestic pharma companies with strong brands and inorganic growth strategies. While acknowledging Divi’s Lab’s challenges with Entresto generics, they find its valuation overstretched. The firm sees growth potential in asset-light hospital chains but emphasizes stock-specific valuation analysis.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets